At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 35 enrolled
Drug / intervention
Mirabegrondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder
In Brief
A Phase 3 clinical trial evaluating Mirabegron for Overactive Bladder and Urinary Incontinence. Completed, enrolled 35 participants.
Detailed Summary
The objective is to evaluate the efficacy and safety of adding mirabegron to an antimuscarinic to treat urinary incontinence in children with Overactive Bladder that are refractory to antimuscarinics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder, Urinary Incontinence
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2013
First PostedJun 2015
Primary CompletionApr 2016
Study CompletionJun 2016
TodayJul 2026
First PostedJun 19, 2015
Enrollment StartApr 1, 2013
Primary CompletionApr 1, 2016
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 11.0 years ago
Interventions
Mirabegrondrug
Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).